Cost-effectiveness of Tipranavir in HIV Treatment
Author Information
Author(s): Hubben Gijs AA, Bos Jasper M, Veltman-Starkenburg Christa A, Stegmeijer Simon, Finnern Henrik W, Kappelhoff Bregt S, Simpson Kit N, Tramarin Andrea, Postma Maarten J
Primary Institution: University Center for Pharmacy, University of Groningen, The Netherlands
Hypothesis
Is the cost-effectiveness of tipranavir better than that of comparator protease inhibitors in HIV patients previously exposed to antiretroviral therapy?
Conclusion
Tipranavir is estimated to be cost-effective compared to comparator protease inhibitors for HIV treatment in the Netherlands.
Supporting Evidence
- The TPV/r regimen resulted in 0.52 life years gained compared to CPI/r.
- The incremental cost-effectiveness ratio for TPV/r was approximately €42,500 per QALY.
- Patients receiving TPV/r had a higher accumulated effect of 6.31 QALYs compared to 5.80 QALYs for CPI/r.
- The total cost per patient for TPV/r was €167,200 compared to €145,400 for CPI/r.
Takeaway
This study looks at how much it costs to help HIV patients live longer and healthier lives with a new medicine called tipranavir compared to an older one.
Methodology
A 3-stage Markov model was used to compare costs and effects of two treatment regimens over a lifetime for 1000 patients.
Potential Biases
Potential bias due to reliance on data from a clinical trial with primarily non-Dutch participants.
Limitations
The model's transition probabilities were based on a US cohort, which may not fully represent the Dutch population.
Participant Demographics
HIV-1 infected patients previously treated with antiretroviral therapy in the Netherlands.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website